HRP20181079T1 - Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja - Google Patents
Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja Download PDFInfo
- Publication number
- HRP20181079T1 HRP20181079T1 HRP20181079TT HRP20181079T HRP20181079T1 HR P20181079 T1 HRP20181079 T1 HR P20181079T1 HR P20181079T T HRP20181079T T HR P20181079TT HR P20181079 T HRP20181079 T HR P20181079T HR P20181079 T1 HRP20181079 T1 HR P20181079T1
- Authority
- HR
- Croatia
- Prior art keywords
- sirna
- use according
- eye
- administered
- treatment
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims 18
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. siRNK usmjerena na SEK ID BR: 1 za primjenu u liječenju suhog oka i/ili boli u oku gdje je siRNK administrirana u dozi od oko 0.3 do oko 0.9 mg po danu.
2. siRNK za primjenu prema patentnom zahtjevu 1 gdje je siRNK administrirana u dozi od oko 0.6 mg ili oko 0.9 mg po oku po danu.
3. siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana tokom 5-15 dana.
4. siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana tokom 10 dana.
5. siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana kronično.
6. siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je spoj definiran kao SEK ID BR: 2.
7. siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana lokalno na oko.
8. Medicinski komplet za liječenje suhog oka i/ili boli u oku koji sadrži količinu siRNK usmjerenu na SEK ID BR: 1, dozator sa otvorom za doziranje doze od oko 0.3 do oko 0.9 mg siRNK u kapljici unaprijed određene zapremine, i tiskane instrukcije za administriranje siRNK usmjerene na SEK ID BR:1 u skladu sa patentnim zahtjevima 1 do 7 u dozi od oko 0.3 do oko 0.9 mg za dnevnu administraciju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1215857.2A GB201215857D0 (en) | 2012-09-05 | 2012-09-05 | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| PCT/EP2013/068245 WO2014037377A1 (en) | 2012-09-05 | 2013-09-04 | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP13759707.6A EP2893019B1 (en) | 2012-09-05 | 2013-09-04 | Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20181079T1 true HRP20181079T1 (hr) | 2018-09-07 |
Family
ID=47136985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181079TT HRP20181079T1 (hr) | 2012-09-05 | 2018-07-11 | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9808479B2 (hr) |
| EP (1) | EP2893019B1 (hr) |
| JP (2) | JP2015529210A (hr) |
| KR (1) | KR102136539B1 (hr) |
| CN (2) | CN104640988A (hr) |
| AU (1) | AU2013311781B2 (hr) |
| BR (1) | BR112015004469B8 (hr) |
| CA (1) | CA2883040C (hr) |
| CL (1) | CL2015000537A1 (hr) |
| CY (1) | CY1121000T1 (hr) |
| DK (1) | DK2893019T3 (hr) |
| EC (1) | ECSP15009391A (hr) |
| ES (1) | ES2685346T3 (hr) |
| GB (1) | GB201215857D0 (hr) |
| HK (1) | HK1212377A1 (hr) |
| HR (1) | HRP20181079T1 (hr) |
| HU (1) | HUE040096T2 (hr) |
| IL (1) | IL237389B (hr) |
| IN (1) | IN2015DN02501A (hr) |
| LT (1) | LT2893019T (hr) |
| MX (1) | MX362854B (hr) |
| PE (1) | PE20150619A1 (hr) |
| PL (1) | PL2893019T3 (hr) |
| PT (1) | PT2893019T (hr) |
| RS (1) | RS57620B1 (hr) |
| RU (1) | RU2663100C2 (hr) |
| SG (1) | SG11201501386TA (hr) |
| SI (1) | SI2893019T1 (hr) |
| WO (1) | WO2014037377A1 (hr) |
| ZA (1) | ZA201501494B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6165723B2 (ja) | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| CN113453686A (zh) | 2019-02-15 | 2021-09-28 | 诺华股份有限公司 | 治疗眼表痛的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| JP5578388B2 (ja) | 2002-04-18 | 2014-08-27 | オプコ ファーマシューティカルズ、エルエルシー | 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法 |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| US20040146858A1 (en) | 2002-07-24 | 2004-07-29 | Immusol, Inc. | Novel siRNA gene libraries and methods for their production and use |
| US20040115815A1 (en) | 2002-07-24 | 2004-06-17 | Immusol, Inc. | Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker |
| PT1527176E (pt) | 2002-08-05 | 2007-04-30 | Atugen Ag | Novas formas de muléculas de arn de interferência |
| US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| WO2004042024A2 (en) | 2002-11-01 | 2004-05-21 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
| DE10322662A1 (de) | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| EP1636342A4 (en) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMERIC COMPOUNDS FOR GENE MODULATION |
| WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20050039573A (ko) | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| KR20150006902A (ko) * | 2003-12-03 | 2015-01-19 | 코다 테라퓨틱스 (엔지) 리미티드 | 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법 |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2005076998A2 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
| WO2006020768A2 (en) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| US8030284B2 (en) | 2004-08-23 | 2011-10-04 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| CA2598234A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| CN101517081A (zh) * | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi介导的Gremlin抑制用于治疗眼内压相关的状况 |
| US20110160279A1 (en) | 2007-08-13 | 2011-06-30 | Board Of Trustees Of Southern Illinois University | METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| CN201337650Y (zh) * | 2009-01-06 | 2009-11-04 | 河北科技大学 | 一次性药用单剂量液体容器 |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
-
2012
- 2012-09-05 GB GBGB1215857.2A patent/GB201215857D0/en not_active Ceased
-
2013
- 2013-09-04 ES ES13759707.6T patent/ES2685346T3/es active Active
- 2013-09-04 HU HUE13759707A patent/HUE040096T2/hu unknown
- 2013-09-04 IN IN2501DEN2015 patent/IN2015DN02501A/en unknown
- 2013-09-04 MX MX2015002802A patent/MX362854B/es active IP Right Grant
- 2013-09-04 PE PE2015000282A patent/PE20150619A1/es not_active Application Discontinuation
- 2013-09-04 LT LTEP13759707.6T patent/LT2893019T/lt unknown
- 2013-09-04 SI SI201331090T patent/SI2893019T1/sl unknown
- 2013-09-04 US US14/425,459 patent/US9808479B2/en active Active
- 2013-09-04 SG SG11201501386TA patent/SG11201501386TA/en unknown
- 2013-09-04 JP JP2015530372A patent/JP2015529210A/ja active Pending
- 2013-09-04 BR BR112015004469A patent/BR112015004469B8/pt active IP Right Grant
- 2013-09-04 EP EP13759707.6A patent/EP2893019B1/en active Active
- 2013-09-04 AU AU2013311781A patent/AU2013311781B2/en active Active
- 2013-09-04 CA CA2883040A patent/CA2883040C/en active Active
- 2013-09-04 WO PCT/EP2013/068245 patent/WO2014037377A1/en active Application Filing
- 2013-09-04 PL PL13759707T patent/PL2893019T3/pl unknown
- 2013-09-04 DK DK13759707.6T patent/DK2893019T3/en active
- 2013-09-04 CN CN201380046215.0A patent/CN104640988A/zh active Pending
- 2013-09-04 RS RS20180877A patent/RS57620B1/sr unknown
- 2013-09-04 PT PT13759707T patent/PT2893019T/pt unknown
- 2013-09-04 KR KR1020157006165A patent/KR102136539B1/ko active IP Right Grant
- 2013-09-04 CN CN201810353730.8A patent/CN108354944A/zh active Pending
- 2013-09-04 RU RU2015112121A patent/RU2663100C2/ru active
-
2015
- 2015-02-24 IL IL237389A patent/IL237389B/en active IP Right Grant
- 2015-03-04 CL CL2015000537A patent/CL2015000537A1/es unknown
- 2015-03-04 ZA ZA2015/01494A patent/ZA201501494B/en unknown
- 2015-03-12 EC ECIEPI20159391A patent/ECSP15009391A/es unknown
-
2016
- 2016-01-05 HK HK16100039.5A patent/HK1212377A1/xx unknown
-
2018
- 2018-05-09 JP JP2018090693A patent/JP6742362B2/ja active Active
- 2018-07-11 HR HRP20181079TT patent/HRP20181079T1/hr unknown
- 2018-08-10 CY CY181100845T patent/CY1121000T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181079T1 (hr) | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja | |
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| BR112014015482A8 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| CO6241170A2 (es) | Administracion de oligonucleotidos antisentido complementarios a la apolipoproteina b humana | |
| WO2011053792A3 (en) | Methods and compositions for sustained delivery of drugs | |
| JP2008044951A5 (hr) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
| NZ592217A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| IL291556B1 (en) | Methods and compositions for administration of arylsulfatase A to the central nervous system | |
| PE20081578A1 (es) | Formulacion en polvo de valganciclovir | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2011503044A5 (hr) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| RU2015109296A (ru) | Системы доставки лекарственного средства и способы лечения рака мочевого пузыря, включающие применение оксалиплатина | |
| JP2018138596A5 (hr) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| RU2019118647A (ru) | Композиции с кариофилленом, устройства для их введения и способы их использования | |
| MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia | |
| BR112013006632A2 (pt) | composições e sistema de liberação de distribuição de droga aprimorados | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas |